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Solitary plasmacytoma (SP) is characterized by a mass of neoplastic monoclonal plasma cells in either bone (SBP) or soft tissue
without evidence of systemic disease attributing to myeloma. Biopsy conﬁrmation of a monoclonal plasma cell inﬁltration from
a single site is required for diagnosis. The common presentation of SBP is in the axial skeleton, whereas the extramedullary
plasmacytoma (EMP) is usually seen in the head and neck. The ratio of SP seen at males to females is 2:1 and the median
age of patients is 55 years. The incidence rate of SP in black race is approximately 30% higher than the white race. Incidence rate
increasesexponentiallybyadvancingage. SBPhasasigniﬁcanthigherriskforprogressiontomyeloma,andthechoiceoftreatment
is radiotherapy (RT) that is applied with curative intent at min. 4000cGy. By only RT application, long-term disease-free survival
(DFS) is possible for approximately 30% of patients with SBP and 65% of patients with EMP.
1.Background
The solitary plasmacytoma (SP) is characterized by a
localized accumulation of neoplastic monoclonal plasma
cells without a proof of a systemic plasma cell proliferative
disorder.Itisaninfrequentformofplasmacellneoplasmand
represents 5% to 10% of all plasma cell neoplasms according
to the literature [1–5]. It can be classiﬁed into 2 groups
regarding to location; deﬁned as solitary plasmacytoma of
the bone (SBP) and extramedullary plasmacytoma (EMP)
[1, 6]. SP mostly occurs in the bones of the axial skeleton,
such as vertebra and skull [1, 2]. The EMP is generally
observed in the head and neck and most frequently in the
nasalcavityandnasopharynx[5,7,8].Themedianageofthe
patients with either SBP or EMP is 55 years [1]. The male-
to-female ratio of SP is 2:1 [5, 7–10]. Incidence rate rises
exponentially by advancing age; however, it is less prominent
at older ages in comparison with multiple myeloma (MM)
[11,12].TheincidencerateofSPinblackraceisaround30%
higher than white race [11, 12].
2.DiagnosisandStaging
The diﬀerentiation criteria for both SBP and EMP from
myeloma is lack of CRAB (increased calcium, renal insuf-
ﬁciency, anemia, or multiple bone lesions) features. Diag-
nostic analysis consists of history, physical examination,
complete blood count, bone marrow biopsy, serum pro-
tein electrophoresis, evaluation of the urine for myeloma
protein, and skeletal survey. The diagnosis of SBP requires
solitary bone lesion conﬁrmed by skeletal survey, plasma cell
inﬁltration proven by biopsy, normal bone marrow biopsy
(<10% plasma cells), and lack of myeloma-related organ
dysfunction [13]. Diagnostic criteria of extramedullary
plasmacytoma (EMP) are tissue biopsy-indicating mon-
oclonal plasma cell histology, bone marrow plasma cell
inﬁltration less than 5% of all nucleated cells, absence
of osteolytic bone lesions or other tissue involvement
without proof of myeloma, hypercalcemia or renal fail-
ure, and low-serum M protein concentration, if exists
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According to the Durie and Salmon staging system,
solitaryboneplasmacytomasareregardedasstageImyeloma
[13]. Therefore, stage I myeloma contains all of the following
criteria: hemoglobin > 10g/dL, normal level of serum
calcium, normal bone structure or solitary plasmacytoma
only, and low M-component (IgG < 5g/dL, IgA < 3g/dL,
urine light chains < 4g/24h)[12, 13].
Changes in laboratory results of secretory plasmacy-
toma generally indicate immunoglobulin production, blood
calcium level alterations, kidney dysfunction, and ele-
vated serum β-2-microglobulin levels. Moreover, secretory
plasmacytoma may be associated with POEMS syndrome
(Polyneuropathy, Organomegaly, Endocrinopathy, Multiple
myeloma, and Skin changes) [14].
Skeletal survey is beneﬁcial to detect osteoblastic re-
sponse to bone destruction. Nevertheless, computed tomog-
raphy (CT) may be more helpful to detect the extent of
bone destruction, and magnetic resonance imaging (MRI)
may also be helpful to determine the multiple vertebra
lesions or bone marrow disease [15]. The lesions are darker
or isointense on T1-weighted images and hyperintense on
T2-weighted images and contrast enhanced [16]. Upon the
detection of multiple vertebra lesions or positivity on 18F-
ﬂuorodeoxyglucose positron emission tomography (FDG-
PET) or bone marrow disease, some patients having been
suspected SPB will be upstaged for MM [17, 18].
3. Prognostic Factors
There are three patterns of failure, these are development of
MM, local recurrence, and development of new bone lesions
without MM [19]. In comparison with EMPs, SBPs have
poor prognosis [20]. SBP has a signiﬁcantly higher risk for
progression to myeloma at a rate of 65–84% in 10 years
and 65–100% in 15 years. In spite of a curative treatment,
the median time to progression to MM is 2 to 3 years [20–
26]. The 10-year overall survival (OS) rate is 70% in EMP
[2, 7–9, 11, 27]. Patients with EMP have improved survival
period when compared to patients with SBP that develops
into MM in 50–60% of patients [1, 26, 28–30]. Patients with
EMP that progressed to MM had a 100% 5-year survival rate
as compared to 33% for SBP [31]. In a review of 721 EMP
cases by Alexiou et al., after treatment, approximately 65% of
the patients had no recurrence and did not progress to MM,
whereas 22% experienced recurrence, and 15% of the cases
evolved into MM [7].
There are controversial reports with respect to the factors
that inﬂuence the risk and frequency of progression to MM
such as age [3, 20, 21, 23, 24, 28, 32, 33]. In our previous
study, younger age was an independent good prognostic
factor for progression to MM (The respective hazard ratio
was 0.295, P = 0.027, 95% CI: 0.100–0.871) [24]. For
instance, Knobel et al. analyzed that younger patients,
especially with vertebral localization, had the best outcome
when treated with moderate dose (≥30Gy) RT [25].
For SBP, some series have detected that a lesion size of
minimum 5cm, age (e.g., patients aged 40 years and over),
spine lesions, RT dose, high M protein levels, existence of
light chains, and persistence of M protein after treatment,
inﬂuence the outcome in these patients and may indicate the
presence of higher risks of progression to MM [4, 19, 21,
23, 25, 26, 30, 32–35]. The determination of the prognostic
factors of EMPs is complicated by the small number of
documented cases and alteration of biological behaviour.
Although the lesion size was reported as the prognostic
feature for conversion of SBP into MM, the literature
contains conﬂicts on this matter [4, 21, 26, 32, 33]. In their
study, Tsang et al. showed that patients with lesions < 5cm
had a local control rate of 100%, whereas patients with
larger tumors had a rate of nearly 40% [32]. In our previous
study on solitary plasmacytomas, a statistically signiﬁcant
relationwasdeterminedduringaunivariateanalysisbetween
macroscopic tumor existence prior to RT and OS or MMFS.
Surgical treatment with RT may be concluded as positive
prognostic factor for PFS which may be an indicator for the
importance of local tumor bulk for disease progression of
patients receiving RT [24].
In most of SBP patients, following RT application, Mon-
oclonal protein is signiﬁcantly decreased; however, protein
disappearance is observed in 20–50% of the patients [1, 26,
35]. In patients with SBP, the disappearance of myeloma
protein with involved-ﬁeld RT predicted long-term DFS
and possible treatment [26, 35]. Posttreatment persistent
myeloma protein was an adverse prognostic factor, for which
adjuvant systemic therapy should be considered [35]. In a
study by Wilder et al., the rate of 10-year myeloma-free
survival (MMFS) was 91% as compared to 29% in patients
with SBP whose M-protein did or did not resolve 1 year after
radiation therapy (RT) [35]. On the other hand, in Mayo
Clinic experience [23], proof of abnormal serum and/or
urine protein was found in 25 out of 46 patients with solitary
plasmacytoma of bone. Presence of abnormal proteins even
after RT, did not aﬀect both survival and DFS. Local failure
has not been observed at the patients who received 45Gy or
more to the solitary lesion.
Many of these ﬁndings may indicate the presence of
indolentmyeloma[1,19].Hence,MMmaybecomeapparent
as soon as the local disease is treated. The new bone
lesions, detected as either generalized osteopenia or new
abnormalities on MRI studies, may indicate progression
to symptomatic MM. The persistence of the M-protein
detected following RT or a suppression of the normal
immunoglobulin classes may accompany these radiologic
abnormalities. In this case, systemic treatment, adjusted for
MM, may be applied [21–23, 26, 27].
Pathological factors have been investigated in some
studies [22, 36]. It is reported that anaplastic type plasma-
cytomas, presenting a higher histologic grade, [36] and the
existence of a high level of angiogenesis [22] are linked to
a poor outcome. Kumar et al. examined whether increased
angiogenesis may help to identify the patients likely to
progress to myeloma. High-grade angiogenesis was present
in 64% of plasmacytomas in their study on plasmacytoma
biopsy samples, and these patients were more likely to
progress to myeloma and had shorter progression-free
survival (PFS) as compared to the patients with low-grade
angiogenesis (P = .02) [22]. Anaplastic plasmacytomasThe Scientiﬁc World Journal 3
Table 1: Solitary plasmacytoma of bones: representative treatment
results.
Author n f/u LC (%) PMM (%) OAS (%)
Wilder et al. [35]6 0 9 4 m o 9 0 6 2 5 9
Knobel et al. [25] 206 56 mo 79 51 50
Tsang et al. [32]3 2 9 5 m o 8 7 6 4 6 5
Kilciksıze ta l .[ 24]5 7 2.4 y9 4 4 . 1 y 6 8
Frassica et al. [23]4 6 9 0 8 9 5 4 4 5
Bataille and Sany [33] 114 >10 y 88 58 68
Galieni et al. [40]3 2 6 9 m o 9 1 6 8 4 9
mo: months, y: years f/u: Median followup, LC: Local control (10-year rate),
PMM: progression to myeloma (10-year rate), and OAS: over all survival
(10- year rate).
have some common pathologic and clinical characteristics
with aggressive B-cell lymphomas and can develop in
the circumstances of immunosuppression and Epstein-Barr
virus infection [37].
4. Treatment
4.1. Radiotherapy. The treatment of SP is largely composed
of retrospective studies of small numbers of patients due to
its rarity (Tables 1 and 2). Currently, the standard care for
SBP is deﬁnitely RT. In some cases, surgical intervention may
be required for bone instability or for rapidly progressive
neurological symptoms like spinal cord compression [12, 38,
39]. The results with surgery alone are not optimal and carry
high rates of local recurrence [3].
SBP is a highly radiosensitive disease, for which excellent
local control rates (greater than 80%) can be achieved with
RT alone [3, 10, 24, 41]. Therefore, RT should be used even
after gross total excision to eradicate microscopic residual
disease in SBP patients. Even though the optimal dose of RT
has not yet been established for SBP, it is recommended that
a radiation dose of at least 40Gy in four weeks is necessary to
obtain local control [23, 31, 42]. Mendenhall et al. reported
a local control rate of 94% with doses over 40Gy, which
dropped to 64% when patients received less than 40Gy [31].
In our previous study, lower radiation doses (<50Gy) were
not associated with a signiﬁcant diﬀerence in local control
rates; however, they were associated with signiﬁcantly lower
PFS [(HR) 2.279; P = 0.044, 95% CI 1.021 to 5.091].
Additionally, approximately 30% of our patients with SBP,
whoreceived≥50Gy,remainedwithoutevidenceofanylocal
disease failures [24]. In clinical practice, a radiation dose of
45–50Gy in 4.5–5 weeks is recommended if allowable by
normal tissue tolerances. Although a precise deﬁnition of
a dose/response relationship has not been clearly demon-
strated for SP, preponderance of data suggests that higher
doses and treatment with curative-intent required curing the
disease, particularly for patients with bulky lesion.
Since the majority of EMP occurs in the head and neck
region and radical surgery with curative intent is generally
a mutilating procedure, it should be treated with curative-
intentRTinsteadofradicalsurgery[5,6,8,41].However,for
patients with EMP in other areas, complete surgical removal
Table 2: Solitary Extramedullary Plasmacytoma: Representative
Treatment Results.
Author n f/u LC (%) PMM (%) OAS (%)
Kilciksiz et al. [24]2 3 2.4 y9 5 7 . 4 y 8 9
Ozsahin et al. [3]5 2 5 6 7 4 3 6 7 2
Galieni et al. [40] 46 118 92 15 78 (15 y)
Tournier-Rangeard [42] 17 80.5 88.2 63.8 63.4
Strojan et al. [43]2 6 6 1 8 7 8 6 1
Leibross et al. [44] 22 — 95 32 56
Chao et al. [45] 16 66 100 31 54
should be considered. If patients are treated with primary
surgery, RT will only be required in case of inadequate
surgical margins [7].
In terms of RT-treatment volume deﬁnition, using MR
imaging for GTV deﬁnition oﬀers several advantages over
conventional imaging methods, such as staging of the disease
andtargetingradiationvolumeswithgreaterprecisiondueto
high soft-tissue contrast and multiplanar imaging [36, 46–
48]. It is also excellent for use in follow-up examinations
during therapy, as it allows veriﬁcation of reduction in
tumor size [49, 50]. However, CT should be considered
in detecting any underlining bone abnormality. Treatment
ﬁelds should be designed to encompass all diseases observed
on MRI and CT scan and should include a margin of healthy
tissue. The optimal target volume for RT planning in SPB is
controversial.Someauthorsrecommendincludingthewhole
bone in the radiation ﬁeld because of the reported marginal
recurrences [28], whereas others recommend including the
partial-involved bone [26, 32, 45]. Common practice for
radiation ﬁelds is to encompass a margin of at least 1.5–
2cm on the tumor shown on MRI as a CTV margin and 5–
10mm as a PTV margin. Prophylactic regional lymph node
irradiation is not necessary in SPB, as the regional nodal
failure rate is low after local RT without intentional coverage
ofadjacentnodes[26,32,36,51].Incaseofvertebralinvolve-
ment, ﬁelds typically include 1- to 2-uninvolved vertebrae
above and below the aﬀected level [38, 52]. The optimal
RT target volume is similarly controversial in EMP patients,
particularly in head and neck localizations that account for
more than 80% of the cases. Addition of elective nodal
irradiation to the RT treatment portals provides excellent
local control rates. However, it signiﬁcantly increases the
acute and late morbidity [26]. Studies reported excellent
nodal control rates as well, without elective nodal irradiation
[32, 36, 51]. Only patients with primary tumor localized at
Waldeyer’s ring received elective nodal irradiation to the ﬁrst
echelon cervical nodes in a study [32]. Due to its morbidity,
elective nodal irradiation is not recommended routinely
in EMP patients. The RT target volume including cervical
lymph nodes is recommended only if clinically involved,
or, at high risk, for example, in case of the primary sites
involving Waldeyer’s ring. Conformal RT using parallel-
opposed ﬁelds is the most commonly used method to cover
the PTV. However, IMRT technique might be considered in
some cases to spare the critical structures, such as eyes and
salivary glands.4 The Scientiﬁc World Journal
4.2. Surgery. For optimal treatment with suﬃcient local
control, a moderate-dose RT combined with surgery (S)
is occasionally suggested [9, 20, 21, 28, 32, 36, 53, 54].
Depending on the resectability of the extramedullary lesion,
RT combined with surgery may be an acceptable treatment
method [8–10, 41]. Despite other studies [51], in our
previous study [24], on multivariate analysis, which the
median followup was 2.41 years, we found that both a higher
dose of radiation and the combination of RT and surgery
predicted for better PFS for overall group and SBP subgroup
rather than RT alone.
In a review of more than 400 publications between 1905
and 1997, Alexiou et al. reported evidence that surgery
alone yielded the best consequences for EMP when negative
surgical margins were obtained [7]. Combined therapy is
suggested when complete surgical tumor resection can not
be applied and/or lymph node areas are eﬀected. Meanwhile,
these are the results of retrospective studies and require
conﬁrmation by prospective randomized trials.
4.3. Chemotherapy. In most series, adjuvant chemotherapy
(CHT) has no beneﬁcial eﬀect on disease control or preven-
tion of progression to multiple myeloma [40, 54]. A survival
advantage was stated in a study that compared adjuvant
melphalanandprednisonegivenforthreeyearsafterRTwith
“RT alone”. Nevertheless, the study concerned included a
small number of patients [55]. For the patients with tumors
larger than 5cm and high-grade histology, adjuvant CHT
may be considered [29]. CHT may also be considered to
unresponded patients to RT. Treatment schedules which are
eﬀective against multiple myeloma can be considered for
these patients [29]. Holland et al. showed that CHT delays
the progression time of plasmacytoma to MM. Nevertheless,
its use did not decrease the conversion rate [21]. Besides,
after progression to MM, the patients, who received CHT,
had the same survival time as those patients who did not
receive CHT [21]. Furthermore, it is suggested that early
exposure to CHT may speed up the progression of resistant
subclones and, therefore, limit later therapeutic options,
when they may be more beneﬁcial [1]. In addition, in one
series, secondary leukemia developed in 4 of 7 patients with
SBP who received adjuvant melphalan-based CHT after RT
had been completed [56].
5.Followup andFurther OutpatientCare
PatientsarereevaluatedwiththemeasurementsofM-protein
andcompletebloodcountsforprogressionanddevelopment
of MM. It should be repeated at 6-week intervals for the ﬁrst
6 months and then with prolongation of clinic visits. If a new
bone pain takes place, additional workup like appropriate
imaging will be needed [57].
6. Conclusions
The most common pattern of recurrence is not local relapse
but systemic myeloma progression, being the main problem
for the prognosis of the disease. Moreover, progression to
M Mm a yp r o b a b l yb er e l a t e dw i t hf a c t o r ss u c ha sa g er a t h e r
than local treatment.
The diagnosis and staging of plasmacytoma need an
evaluation with more speciﬁc histological, phenotypic, and
radiographic methods in order to exclude occult MM and
other plasma cell neoplasm. Also, there is a need for further
prospective studies with large series evaluating SBP and EMP
separately to elucidate the argument on prognostic factors
and treatment options of the disease. Close cooperative work
done by a team of a hematologist, a radiotherapist, and a
surgeon will ensure the best results after the treatment.
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